Consider Keeping (NYSE American: NNVC) On Your Radar As Updates Arrive From The DRC

Catch Monday's pre-market mover?

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Consider Keeping (NYSE American: NNVC) On Your Radar As Updates Arrive From The DRC *Get Our Updates Faster—Tap Here To Receive SMS Alerts* September 29th Greetings, Friend! Catch Monday's pre-market mover? Brought into focus on Sunday following a Friday close of $1.62, it rocketed to a high of $2.79 ahead of Monday's bell. That short-term surge resulted in a move of approx. 72%. As that move was underway, we caught a whiff of something else that grabbed our attention. Deep in Ituri province, in the eastern Democratic Republic of Congo, patients at an E-bola Treatment Center have started receiving a treatment that dissolves in the mouth. There’s no IV line, no infusion pump, and no needle for health care workers to handle. That treatment is NV-387, and the company behind it is NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral developer based in Shelton, Connecticut. The company confirmed on Monday that enrollment and dosing in its Phase II E-bola trial began on or about September 23rd, with Prof. Patrick de Marie Chimusa Katoto leading the study. The trial is an adaptive Phase IIA/IIB design, starting with a dose run-in before moving into a randomized, controlled efficacy stage. The backdrop is sobering. The Bund-ibugyo E-bola outbreak now stands at 7,890 confirmed cases and 3,799 confirmed deaths as of September 23rd, per WHO figures. The WHO-backed PARTNERS study is testing an antibody cocktail and remdesivir, both delivered by infusion. NanoViricides says NV-387 is the only orally administered therapy in clinical trials for this outbreak, to the best of its knowledge. Sources: NanoViricides Press Release (Sept. 8th, 15th, & 28th, 2026) A second front opened last week. The company’s Phase II clinical study in M-pox infections began enrolling patients in Lodja, Sankuru province, led by Prof. Vivi Maketa Tevuzula of the University of Kinshasa.   It’s the first Phase II trial of NV-387 in any indication, and the company notes there’s currently no approved therapy for this infection. Behind The Scenes In a roughly 30-minute fireside chat hosted by IPO Edge, President and Executive Chairman Anil R. Diwan, PhD, laid out the core idea. NV-387 mimics heparan sulfate proteoglycan (HSPG), a host-cell feature the company says most disease-causing viral pathogens need to attach to cells. If a pathogen mutates, it still needs that docking point. Diwan also struck a measured tone in Monday’s release: “It is the data from the clinical trial that will tell us if NV-387 is effective.” That brings us to the bigger shift. NanoViricides has moved from a Phase I story to a multi-indication field program. NV-387 completed its Phase I trial in healthy subjects with no reported adverse events, and the FDA granted Orphan designation for meas-les on April 27th. The company has since secured a Rare Pediatric Disease designation for meas-les as well, which could potentially make it eligible for a Priority Review Voucher upon approval. About The Company: NanoViricides, Inc. NanoViricides builds broad-spectrum antiviral candidates on its nanoviricide platform, licensed from TheraCour Pharma. Lead asset NV-387 comes in several formulation, including oral gum-mies, an oral syrup, and solutions for injection, infusion, and inhalation. The pipeline also includes NV-HHV-1 for shingles, plus earlier programs spanning influenza, RSV, dengue, and rabies. The company is pre-revenue. It owns a debt-free, cGMP-capable facility that handles R&D and clinical supply manufacturing. More Sources: NNVC Website. 6 Potential Catalysts Putting (NYSE American: NNVC) At The Top Of Our Watchlist This Week #1. Two Phase II Trials Now Dosing Patients in Central Africa. With both the E-bola and pox studies enrolling since late September, NNVC could potentially generate its first Phase II safety and efficacy readouts from two separate indications. #2. An Oral Option in an Outbreak Dominated by Infusions. Because infusions are hard to scale in resource-poor regions, the room-temperature, dissolve-in-the-mouth format highlighted in the E-bola release may give NNVC a potential logistical edge if the data holds up. #3. Meas-les Designations Put a Potential Priority Review Voucher in Play. Holding both Orphan and Rare Pediatric Disease designations, NNVC could potentially earn a voucher on approval, and the company notes one recently changed hands for $195Mn. #4. Low Float Setup With Under 22Mn Shares Available. According to Yahoo Finance, the float sits near 21.08Mn shares, making NNVC a low float idea where the potential for heightened volatility may be significant. #5. Multiple Barchart Technical Indicators Are Flashing Bullish. Long and medium-term moving average crossovers lead the way for NNVC on Barchart’s opinion page, with their composite “Trend Seeker” indicator triggered as well at close on Monday. #6. Published Coverage Carries A $6.00 Target Price. Noble Capital Markets reiterated last week with a continued Outperform rating, giving NNVC a documented third-party reference point. The Bottom Line NanoViricides, Inc, (NYSE American: NNVC) spent years building a platform and a Phase I safety record. Now the real test has started, in the field, against two infections with no approved therapy.  The company has been clear that results will decide what comes next, and that’s the right way to frame it. For market watchers following pan-demic preparedness, out-break response, and rare pediatric designations, NNVC now sits at the center of all three. Coverage is officially underway on NanoViricides, Inc, (NYSE American: NNVC). Be on the lookout for updates coming soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 09/28/2026 and ending on 09/29/2026 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid forty two thousand five hundred USD ("Funds"). These Funds were part of the fifteen thousand USD funds that TD Media LLC received from a third party named Interactive Offers LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NNVC:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/nnvc-0cgo7/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice